Technology | Leads Implantable Devices | May 15, 2017

FDA Clears Medtronic's MR-conditional Quadripolar CRT-P

Portfolio of next generation heart failure devices offers effective pacing and access to MRI

Percepta, Serena, Solara CRT-P devices with quatripolar leads
medtronic percepta Quad quadrapolar CRT-P, MRI safe lead

May 15, 2017 – The U.S. Food and Drug Administration (FDA) has granted market clearance Medtronic’s portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure. These devices also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (T) machines. The Percepta Quad CRT-P MRI SureScan, Serena Quad CRT-P MRI SureScan and Solara Quad CRT-P MRI SureScan are expected to be available commercially in the United States in early summer 2017. 

“These new pacemakers allow clinicians to provide more personalized therapy treatment options,” said Anne B. Curtis, M.D., chair of the Department of Medicine, University at Buffalo, N.Y. “Their ability to automatically adjust pacing to meet the patient’s needs, even those who are among the most difficult to treat, is an example of how advanced implanted heart device technology has become.”
 
The Percepta Quad CRT-P features the EffectivCRT Diagnostic, which automatically determines the effectiveness of each left ventricular pace, and the EffectivCRT during AF algorithm, which automatically adjusts pacing rates during atrial fibrillation (AF). It also includes VectorExpress 2.0, an automated in-office test that reduces lead programing to two minutes,[1] and reveals clinically actionable information to help physicians select optimal pacing configurations for each patient.
 
The Percepta Quad and Serena Quad CRT-Ps also feature the Medtronic-exclusive AdaptivCRT algorithm, which reduces a patient’s odds of a 30-day heart failure readmission by 59 percent,[2] and has demonstrated a 46 percent reduction in AF risk compared to echo-optimized biventricular pacing.[3] Multiple point pacing, which can stimulate the left ventricle (lower chamber) at two sites, is also available on both devices, as well as on the company’s Claria MRI Quad CRT-D SureScan and Amplia MRI Quad CRT-D SureScan.
 
All three CRT-Ps also are compatible with Attain Performa MRI SureScan Quadripolar Leads, which include short bipolar spacing to reduce the occurrence of phrenic nerve stimulation,[4] steroid on all electrodes, and three shapes for varying patient anatomies. They also employ the Medtronic-exclusive PhysioCurve contoured design, which reduces overall skin pressure compared to non-contoured devices,[5] for enhanced patient comfort6 and improved cosmetic appearance of the implant site7. This CRT-P portfolio received CE (Conformité Européenne) mark in February 2017.
  
For more information: www.medtronic.com

References:
1. Demmer, W. VectorExpress performance results. Medtronic data on file. January 2013.
2. Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. JACC Heart Fail. July 2015;3(7):565-572.
3. Martin D, et al. Clinical outcomes with adaptive cardiac resynchronization therapy: Long-term outcomes of the Adaptive CRT Trial. HFSA Annual Scientific Meeting. September 23, 2013.
4. Biffi et al. Effort of bipolar electrode spacing on phrenic nerve stimulation and left ventricular pacing thresholds: An acute canine study. Circulation Arrhythmia and Electrophysiology. 2012.
5. Flo D, et al. IS4/DF4 Device Shape Analysis. Medtronic data on file. January 2013. 
6. Ceelen KK, et al. J Biomech. 2008;41:3399-3404.
7. Gold MR, et al. J Am Coll Cardiol. 1996;28;1278-1282.

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
Subscribe Now